- Home
- CVAC vs REPL Comparison
CVAC vs REPL Comparison
Compare CVAC & REPL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVAC
- REPL
- Stock Information
- Founded
- CVAC 2000
- REPL 2015
- Country
- CVAC Germany
- REPL United States
- Employees
- CVAC N/A
- REPL N/A
- Industry
- CVAC Biotechnology: Pharmaceutical Preparations
- REPL Biotechnology: Pharmaceutical Preparations
- Sector
- CVAC Health Care
- REPL Health Care
- Exchange
- CVAC Nasdaq
- REPL Nasdaq
- Market Cap
- CVAC 812.1M
- REPL 780.3M
- IPO Year
- CVAC 2020
- REPL 2018
- Fundamental
- Price
- CVAC $4.10
- REPL $10.14
- Analyst Decision
- CVAC Hold
- REPL Strong Buy
- Analyst Count
- CVAC 3
- REPL 6
- Target Price
- CVAC $10.00
- REPL $17.50
- AVG Volume (30 Days)
- CVAC 1.2M
- REPL 794.9K
- Earning Date
- CVAC 11-12-2024
- REPL 02-06-2025
- Dividend Yield
- CVAC N/A
- REPL N/A
- EPS Growth
- CVAC N/A
- REPL N/A
- EPS
- CVAC N/A
- REPL N/A
- Revenue
- CVAC $70,565,734.00
- REPL N/A
- Revenue This Year
- CVAC $742.57
- REPL N/A
- Revenue Next Year
- CVAC N/A
- REPL $300.41
- P/E Ratio
- CVAC N/A
- REPL N/A
- Revenue Growth
- CVAC 75.11
- REPL N/A
- 52 Week Low
- CVAC $2.22
- REPL $4.92
- 52 Week High
- CVAC $5.28
- REPL $17.00
- Technical
- Relative Strength Index (RSI)
- CVAC 62.06
- REPL 32.06
- Support Level
- CVAC $3.89
- REPL $10.00
- Resistance Level
- CVAC $4.32
- REPL $11.20
- Average True Range (ATR)
- CVAC 0.33
- REPL 0.84
- MACD
- CVAC 0.03
- REPL -0.20
- Stochastic Oscillator
- CVAC 54.27
- REPL 3.93
About CVAC CureVac N.V.
CureVac is a biopharmaceutical company headquartered in Germany that is developing vaccines and therapies using messenger ribonucleic acid, or mRNA. The company was founded in 2000 and had its initial public offering in August 2020. CureVac had a collaboration with GSK to develop second-generation seasonal influenza and Covid vaccines and an avian influenza vaccine. The company's other pipeline candidates include mRNA vaccines for oncology and molecular therapies spanning tumors, liver, and ocular diseases.
About REPL Replimune Group Inc.
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3.